CVKD Overview

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.

Wall Street analysts forecast CVKD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cadrenal Therapeutics Inc revenue for the last quarter amounts to -2.51M USD, decreased -35.99

Cadrenal Therapeutics Inc. EPS for the last quarter amounts to -3002217.00 USD, decreased -35.42

Cadrenal Therapeutics Inc (CVKD) has 5 emplpoyees as of July 01 2026.

Today CVKD has the market capitalization of 9.58M USD.